XML 48 R35.htm IDEA: XBRL DOCUMENT v3.25.3
CONDENSED CONSOLIDATING BALANCE SHEET AND STATEMENT OF OPERATIONS (Tables)
9 Months Ended
Sep. 30, 2025
CONDENSED CONSOLIDATING BALANCE SHEET AND STATEMENT OF OPERATIONS  
Schedule of condensed consolidating balance sheet

 

 

Yubo International Biotech Limited (Parent Company)

 

 

Platinum (Cayman Island) and Platinum HK

(Cayman Island)

 

 

Yubo

Global

 

 

Yubo Chengdu

(WFOE)

 

 

Yubo

Beijing

(VIE

Subsidiaries)

 

 

Elimination

 

 

Consolidated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ASSETS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Current Assets

 

$

 

 

$359

 

 

$50,711

 

 

$

 

 

$598,492

 

 

$

 

 

$649,563

 

Investment in subsidiaries and variable interest entity (VIE)

 

 

(2,181,987)

 

 

930,000

 

 

 

 

 

 

 

 

 

 

 

 

1,251,987

 

 

 

 

Intercompany receivables

 

 

 

 

 

 

 

 

439,427

 

 

 

 

 

 

756,253

 

 

 

(1,195,680)

 

 

 

Other assets

 

 

 

 

 

 

 

 

21,667

 

 

 

 

 

 

791,884

 

 

 

(509,903)

 

 

303,648

 

Total Assets

 

$(2,181,987)

 

$930,359

 

 

 

511,805

 

 

 

 

 

 

2,146,630

 

 

 

(453,596)

 

 

953,211

 

LIABILITIES AND SHAREHOLDERS' EQUITY

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total current liabilities

 

$

 

 

$150,000

 

 

$51,380

 

 

$

 

 

$2,353,936

 

 

$

 

 

$2,555,316

 

Intercompany payables

 

 

 

 

 

 

 

 

44,248

 

 

 

 

 

 

1,156,981

 

 

 

(1,201,229)

 

 

 

Other liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Liabilities

 

 

 

 

 

150,000

 

 

 

95,628

 

 

 

 

 

 

3,510,917

 

 

 

(1,201,229)

 

 

2,555,316

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shareholders' Deficit:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Capital stock and additional paid in capital

 

 

 

 

 

1,569,229

 

 

 

840,805

 

 

 

 

 

 

4,718,510

 

 

 

(1,489,241)

 

 

5,639,303

 

Accumulated deficit

 

 

(2,181,987)

 

 

(788,870)

 

 

(424,629)

 

 

 

 

 

(6,082,797)

 

 

1,999,640

 

 

 

(7,478,641)

Accumulated other comprehensive income (loss)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

176,450

 

 

 

176,450

 

Non—controlling interests

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

60,783

 

 

 

60,783

 

Total Deficit

 

 

(2,181,987)

 

 

780,359

 

 

 

416,178

 

 

 

 

 

 

(1,364,287)

 

 

747,632

 

 

 

(1,602,105)

Total Liabilities and Shareholders' Equity

 

$(2,181,987)

 

$930,359

 

 

$511,805

 

 

$

 

 

$2,146,630

 

 

$(453,596)

 

$953,211

 

Schedule of condensed consolidating statement of operations

 

 

Yubo International Biotech Limited (Parent Company)

 

 

Platinum (Cayman Island) and Platinum HK

(Cayman Island)

 

 

Yubo

Global

 

 

Yubo Chengdu

(WFOE)

 

 

Yubo Beijing (VIE

Subsidiaries)

 

 

Elimination

 

 

Consolidated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales of product and services

 

$

 

 

$

 

 

$

 

 

$

 

 

$

 

 

$

 

 

$

 

Cost of goods and services sold

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

902,228

 

 

 

 

 

 

902,228

 

Loss from operations

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(902,228)

 

 

 

 

 

(902,228)

Other income (expense)

 

 

 

 

 

 

 

 

(2)

 

 

 

 

 

(58)

 

 

 

 

 

(60)

Equity in net loss of subsidiaries and variable interest entity (VIE)

 

 

(1,628,906)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1,628,906

 

 

 

 

Net Loss

 

$(1,628,906)

 

$

 

 

$(2)

 

$

 

 

$(902,286)

 

$1,628,906

 

 

$(902,288)